Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Growth Metrics

Guided Therapeutics (GTHP) Receivables - Other (2018 - 2022)

Guided Therapeutics' Receivables - Other history spans 3 years, with the latest figure at $82984.0 for Q4 2022.

On a quarterly basis, Receivables - Other changed N/A to $82984.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $82984.0, a N/A change, with the full-year FY2022 number at $82984.0, changed N/A from a year prior.
Receivables - Other hit $82984.0 in Q4 2022 for Guided Therapeutics, up from $43057.0 in the prior quarter.
Over the last five years, Receivables - Other for GTHP hit a ceiling of $661000.0 in Q3 2018 and a floor of $24785.0 in Q2 2022.
Historically, Receivables - Other has averaged $173637.7 across 3 years, with a median of $91492.0 in 2020.